ArticleGenome medicine2016
Integrating precision cancer medicine into healthcare-policy, practice, and research challenges.
Article in Genome medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Precision cancer medicine in Europe: a mixed-methods study on infrastructure for extended molecular diagnostics.Journal of cancer research and clinical oncology · 2026Article
- Precision Medicine for Cancer and Health Equity in Latin America: Generating Understanding for Policy and Health System Shaping.International journal of environmental research and public health · 2025Review
- Implementing Personalized Cancer Medicine: Insights from a Qualitative Interview Study.Journal of personalized medicine · 2025Article
- How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action.Health science reports · 2023Article
- Pharmacogenetics of ABCB1, CDA, DCK, GSTT1, GSTM1 and outcomes in a cohort of pediatric acute myeloid leukemia patients from Colombia.Cancer reports (Hoboken, N.J.) · 2023Article
- A hybrid algorithm for clinical decision support in precision medicine based on machine learning.BMC bioinformatics · 2023Article
- MMKP: A mind mapping knowledgebase prototyping tool for precision medicine.Frontiers in immunology · 2022Article
- Applications and Biocompatibility of Mesoporous Silica Nanocarriers in the Field of Medicine.Frontiers in pharmacology · 2022Review
- Proteomic Interrogation in Cancer Biomarker.Advances in experimental medicine and biology · 2021Article
- Governing Personalized Health: A Scoping Review.Frontiers in genetics · 2021Article
- Towards Machine-Readable (Meta) Data and the FAIR Value for Artificial Intelligence Exploration of COVID-19 and Cancer Research Data.Frontiers in big data · 2021Article
- Article
- Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives.Briefings in bioinformatics · 2020Review
- Counting Oceanians of Non-European, Non-Asian Descent (ONENA) in the South Pacific to Make Them Count in Global Health.Tropical medicine and infectious disease · 2019Article
- A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine.Applied health economics and health policy · 2019Review
- High-Throughput Architecture for Discovering Combination Cancer Therapeutics.JCO clinical cancer informatics · 2018Article
- Sharing longitudinal, non-biological birth cohort data: a cross-sectional analysis of parent consent preferences.BMC medical informatics and decision making · 2018Article
- Clinical exome sequencing in France and Quebec: what are the challenges? What does the future hold?Life sciences, society and policy · 2018Article
- Article
- Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application.International journal of biomedical investigation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine (PM) can be defined as a predictive, preventive, personalized, and participatory healthcare service delivery model. Recent developments in molecular biology and information technology make PM a reality today through the use of massive amounts of genetic, 'omics', clinical, environmental, and lifestyle data. With cancer being one of the most prominent public health threats in developed countries, both the research community and governments have been investing significant time, money, and efforts in precision cancer medicine (PCM). Although PCM research is extremely promising, a number of hurdles still remain on the road to an optimal integration of standardized and evidence-based use of PCM in healthcare systems. Indeed, PCM raises a number of technical, organizational, ethical, legal, social, and economic challenges that have to be taken into account in the development of an appropriate health policy framework. Here, we highlight some of the more salient issues regarding the standards needed for integration of PCM into healthcare systems, and we identify fields where more research is needed before policy can be implemented. Key challenges include, but are not limited to, the creation of new standards for the collection, analysis, and sharing of samples and data from cancer patients, and the creation of new clinical trial designs with renewed endpoints. We believe that these issues need to be addressed as a matter of priority by public health policymakers in the coming years for a better integration of PCM into healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.